Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy

Abstract

Objective: To validate the feasibility of molecular imaging-monitored intratumoral radiofrequency hyperthermia (RFH) enhanced direct oncolytic virotherapy for hepatocellular carcinoma (HCC). Methods: This study included in vitro experiments using luciferase-labeled rat HCC cells and in vivo validation experiments on rat models with orthotopic HCCs. Both cells and HCCs in four groups (n ¼ 6/group) were treated by: (1) combination therapy of oncolytic virotherapy (T-VEC) plus RFH at 42 C for 30 min; (2) oncolytic virotherapy alone; (3) RFH alone; and (4) saline. For in vitro confirmation, confocal microscopy and bioluminescence optical imaging were used to evaluate the cell viabilities. For in vivo validation, oncolytic viruses were directly infused into rat HCCs through a multi-functional perfusion-thermal RF electrode, followed by RFH. Ultrasound and optical imaging were used to follow up size and bioluminescence signal changes of tumors overtime, which were correlated with subsequent laboratory examinations. Results: For in vitro experiments, confocal microscopy showed the lowest number of viable cells, as well as a significant decrease of bioluminescence signal intensity of cells with combination therapy group, compared to other three groups (p < .001). For in vivo experiments, ultrasound and optical imaging showed the smallest tumor volume, and significantly decreased bioluminescence signal intensity in combination therapy group compared to other three groups (p < .05), which were well correlated with pathologic analysis. Conclusion: It is feasible of using molecular imaging to guide RFH-enhanced intratumoral oncolytic virotherapy of HCC, which may open new avenues to prevent residual or recurrent disease of thermally ablated intermediate-to-large HCCs.

Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy

“…In recent years, immunotherapy, a new treatment strategy, has provided the expected improvement in the treatment response in preclinical animal studies [115], and its application in clinical research has also been growing rapidly and has attracted widespread attention. In this section, we focus on two notable synergistic OVs-mediated treatment options: (1) OVs and immune checkpoint inhibitors (ICIs) and ( 2) OVs combined with CAR-T.…”

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

“…When high doses of T-VEC are injected intratumorally under the guidance of ultrasound and optical imaging techniques, radiofrequency ablation enhances the therapeutic effect of the G47D oncolytic virus in a preclinical (Hu et al, 2021b) study. This dual application opens up a new path for treating larger hepatocellular carcinomas locally, while local injection of the virus reduces the viral therapy's systemic toxicity (Song et al, 2019).…”

Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications

“…They reported that the hyperthermia resulted from the used radiofrequency electrode enhanced the direct oncolytic effect of the virotherapy. [ 104 ] Intratumoral administration has been investigated in a clinical trial involving CAR T‐cells targeting GPC3. In another clinical trial, adenovirus encoding the suicide gene, HSV/Tk, was administered similarly.…”